Journal ArticleDOI
Clinical toxicity of 4'-epi-doxorubicin (epirubicin).
Ganzina F,Di Pietro N,Magni O +2 more
Reads0
Chats0
TLDR
At equimolar doses and in comparative studies, epirubicin proved to induce less acute toxicity than doxorubic in, in particular less vomiting, hair loss and myelotoxicity, while giving a comparable response rate in randomized breast cancer studies.Abstract:
Epirubicin is a new derivative of doxorubicin characterized by an improved spectrum of activity and a better therapeutic index. At equimolar doses and in comparative studies, epirubicin proved to induce less acute toxicity than doxorubicin, in particular less vomiting, hair loss and myelotoxicity. While giving a comparable response rate in randomized breast cancer studies, epirubicin also proved to be less cardiotoxic than doxorubicin. The reduced potential for cardiac toxicity of epirubicin versus doxorubicin has been shown both by functional assessment (radionuclide cinecardioangiography) and by histopathologic evaluation (endomyocardial biopsies) at equally myelosuppressive doses or at equal doses (equimolar). The lessened cardiotoxicity of epirubicin versus doxorubicin can be explained by the different pharmacokinetic and metabolic properties of these two agents: epirubicin has been found to have a more rapid pharmacokinetic plasma clearance and an additional metabolic pathway (unique glucuronidation).read more
Citations
More filters
Journal ArticleDOI
Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
Karlijn A. Wouters,Leontien C. M. Kremer,Tracie L. Miller,Eugene H. Herman,Steven E. Lipshultz +4 more
TL;DR: The most promising current strategies to limit or prevent anthracycline‐induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening are summarised.
Journal Article
Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly Schedule
Frank M. Torti,Michael R. Bristow,Anthony E. Howes,Diana Aston,Frank E. Stockdale,Stephen K. Carter,Marsha Kohler,Byron W. Brown,Margaret E. Billingham +8 more
TL;DR: In this article, endomyocardial biopsy was done 119 times in 98 patients receiving doxorubicin therapy once every 3 weeks and 41 times in 27 patients receiving DOXORUBICIN therapy weekly.
Journal ArticleDOI
Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
Greg L. Plosker,Diana Faulds +1 more
TL;DR: D dose-intensive epirubicin-containing regimens, which are feasible due to its lower myelosuppression and cardiotoxicity, have produced high response rates in early breast cancer, a potentially curable malignancy, as well as advanced breast, and lung cancers.
Journal ArticleDOI
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
TL;DR: The plasma concentration v time curves of (7d)-aglycones showed a second peak between two and 12 hours after injection, suggesting an enterohepatic circulation for metabolites lacking the daunosamine sugar moiety.
Journal ArticleDOI
Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administration.
TL;DR: 6 patients with ovarian carcinoma after simultaneous intravenous administration of equal amounts of the two anthracyclines and their corresponding 13-hydroxy metabolites were studied, with great interindividual variation in the pharmacokinetic parameters.
References
More filters
Journal ArticleDOI
Reporting results of cancer treatment.
TL;DR: Recommendations have been developed for standardized approaches to the recording of baseline data relating to the patient, the tumor, laboratory and radiologic data, the reporting of treatment, grading of acute and subacute toxicity, reporting of response, recurrence and disease‐free interval, and reporting results of therapy.
Journal ArticleDOI
Risk factors for doxorubicin-induced congestive heart failure.
TL;DR: There was a continuum of increasing risk as the cumulative amount of administered drug increased, and a weekly dose schedule of doxorubicin was associated with a significantly lower incidence of congestive heart failure than was the usually employed every 3-week schedule.
Journal ArticleDOI
Dose response evaluation of adriamycin in human neoplasia
Robert M. O'Bryan,Laurence H. Baker,J. E. Gottlieb,Saul E. Rivkin,Stanley P. Balcerzak,G. N. Grumet,Sydney E. Salmon,Thomas E. Moon,B. Hoogstraten +8 more
TL;DR: There were no statistically significant differences in remission rates, durations of remission, or toxicities in the dose schedules studied, and unless rapid remission induction is urgent, the recommend 60 mg/m2 X four doses and measurement of myocardial function if treatment is to continue.
Journal Article
Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly Schedule
Frank M. Torti,Michael R. Bristow,Anthony E. Howes,Diana Aston,Frank E. Stockdale,Stephen K. Carter,Marsha Kohler,Byron W. Brown,Margaret E. Billingham +8 more
TL;DR: In this article, endomyocardial biopsy was done 119 times in 98 patients receiving doxorubicin therapy once every 3 weeks and 41 times in 27 patients receiving DOXORUBICIN therapy weekly.
Journal ArticleDOI
Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly Schedule: Assessment by Endomyocardial Biopsy
Frank M. Torti,Michael R. Bristow,Anthony E. Howes,Diana Aston,Frank E. Stockdale,Stephen K. Carter,Marsha Kohler,Byron W. Brown,Margaret E. Billingham +8 more
TL;DR: Doxorubicin therapy administered on a weekly schedule is associated with less anthracycline-induced cardiac damage than is doxorubICin therapy delivered in the conventional, 3-weekly schedule.